Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
